JP2010502759A - タンパク質物質の経口または直腸投与のための医薬組成物 - Google Patents
タンパク質物質の経口または直腸投与のための医薬組成物 Download PDFInfo
- Publication number
- JP2010502759A JP2010502759A JP2009527791A JP2009527791A JP2010502759A JP 2010502759 A JP2010502759 A JP 2010502759A JP 2009527791 A JP2009527791 A JP 2009527791A JP 2009527791 A JP2009527791 A JP 2009527791A JP 2010502759 A JP2010502759 A JP 2010502759A
- Authority
- JP
- Japan
- Prior art keywords
- tnfα
- active ingredient
- substances
- cytokines
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 title claims abstract description 47
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 230000000968 intestinal effect Effects 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
- 102000014150 Interferons Human genes 0.000 claims abstract description 6
- 108010050904 Interferons Proteins 0.000 claims abstract description 6
- 102000015696 Interleukins Human genes 0.000 claims abstract description 6
- 108010063738 Interleukins Proteins 0.000 claims abstract description 6
- 239000003102 growth factor Substances 0.000 claims abstract description 6
- 229940047122 interleukins Drugs 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims description 35
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 33
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 15
- 102000004127 Cytokines Human genes 0.000 claims description 14
- 108090000695 Cytokines Proteins 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 12
- 208000011231 Crohn disease Diseases 0.000 claims description 9
- 241000792859 Enema Species 0.000 claims description 9
- 239000007920 enema Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
- 210000001072 colon Anatomy 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 230000004968 inflammatory condition Effects 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 210000002784 stomach Anatomy 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 229940095399 enema Drugs 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 210000000664 rectum Anatomy 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 5
- 238000013270 controlled release Methods 0.000 claims description 5
- 210000000936 intestine Anatomy 0.000 claims description 5
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 229940079360 enema for constipation Drugs 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 229940047124 interferons Drugs 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 230000000670 limiting effect Effects 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 239000008247 solid mixture Substances 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 210000001842 enterocyte Anatomy 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 7
- 102000019034 Chemokines Human genes 0.000 abstract description 4
- 108010012236 Chemokines Proteins 0.000 abstract description 4
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 229940079322 interferon Drugs 0.000 abstract description 3
- 230000017074 necrotic cell death Effects 0.000 abstract description 3
- 230000017854 proteolysis Effects 0.000 abstract description 2
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 description 23
- 102000005962 receptors Human genes 0.000 description 23
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000008176 lyophilized powder Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 229940116176 remicade Drugs 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 6
- 229960001375 lactose Drugs 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
- 239000008117 stearic acid Substances 0.000 description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 5
- 239000008119 colloidal silica Substances 0.000 description 5
- 235000019700 dicalcium phosphate Nutrition 0.000 description 5
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 5
- 230000003628 erosive effect Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
- 239000008347 soybean phospholipid Substances 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229960000598 infliximab Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 description 2
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000001731 descending colon Anatomy 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 210000001599 sigmoid colon Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010067993 Mucosal necrosis Diseases 0.000 description 1
- 206010028124 Mucosal ulceration Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229940090100 cimzia Drugs 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 201000009019 intestinal benign neoplasm Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20061741 ITMI20061741A1 (it) | 2006-09-12 | 2006-09-12 | Composizioni farmaceutiche per la somministrazione orale di sostanze proteiche |
| ITMI20071205 ITMI20071205A1 (it) | 2007-06-15 | 2007-06-15 | Composizioni farmaceutiche per la somministrazione orale o rettale di sostanze proteiche |
| PCT/EP2007/059378 WO2008031770A2 (en) | 2006-09-12 | 2007-09-07 | Pharmaceutical compositions for the oral or rectal administration of protein substances |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010502759A true JP2010502759A (ja) | 2010-01-28 |
| JP2010502759A5 JP2010502759A5 (https=) | 2010-10-21 |
Family
ID=39107203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527791A Pending JP2010502759A (ja) | 2006-09-12 | 2007-09-07 | タンパク質物質の経口または直腸投与のための医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100004157A1 (https=) |
| EP (1) | EP2081555A2 (https=) |
| JP (1) | JP2010502759A (https=) |
| KR (1) | KR20090086060A (https=) |
| CA (1) | CA2663548A1 (https=) |
| MX (1) | MX2009002756A (https=) |
| RU (1) | RU2009113557A (https=) |
| WO (1) | WO2008031770A2 (https=) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017521479A (ja) * | 2014-05-15 | 2017-08-03 | ラニ セラピューティクス， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法 |
| JP2018514563A (ja) * | 2015-05-01 | 2018-06-07 | インキューブ ラブズ， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の製作のための薬学的組成物および方法 |
| JP2019514855A (ja) * | 2016-03-31 | 2019-06-06 | ブイエイチスクエアード リミテッド | 組成物 |
| JP2021506894A (ja) * | 2017-12-22 | 2021-02-22 | コスモ・テクノロジーズ・リミテツド | 固体送達組成物 |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US12018090B2 (en) | 2014-05-15 | 2024-06-25 | Rani Therapeutics, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12203056B2 (en) | 2008-03-28 | 2025-01-21 | Ecolab Usa Inc. | Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents |
| US8809392B2 (en) | 2008-03-28 | 2014-08-19 | Ecolab Usa Inc. | Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents |
| GB201017048D0 (en) * | 2010-10-08 | 2010-11-24 | Ucl Business Plc | Composition |
| US10946091B2 (en) * | 2012-06-04 | 2021-03-16 | Gaurav Agrawal | Compositions and methods for treating Crohn's disease and related conditions and infections |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| HK1250011A1 (zh) | 2015-03-31 | 2018-11-23 | Sorriso Pharmaceuticals, Inc. | 具有蛋白酶可切割接头的肽构建体 |
| AU2016261599B2 (en) * | 2015-05-08 | 2021-08-26 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US11491114B2 (en) | 2016-10-12 | 2022-11-08 | Curioralrx, Llc | Formulations for enteric delivery of therapeutic agents |
| CA3045310A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| WO2020254827A1 (en) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
| JP7680377B2 (ja) | 2019-06-21 | 2025-05-20 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| KR20220063148A (ko) | 2019-06-21 | 2022-05-17 | 소리소 파마슈티컬스 인크. | 조성물 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07145068A (ja) * | 1991-08-07 | 1995-06-06 | Yeda Res & Dev Co Ltd | 溶解型ｔｎｆ受容体のマルチマー、その製造方法、およびそれを含有する医薬組成物 |
| JPH10503179A (ja) * | 1994-06-24 | 1998-03-24 | イミュネックス・コーポレーション | 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法 |
| JP2003501457A (ja) * | 1999-06-14 | 2003-01-14 | コスモ ソシエタ ペル アチオニ | 制御放出および味感遮蔽経口医薬組成物 |
| WO2005027878A1 (en) * | 2003-09-19 | 2005-03-31 | Penwest Pharmaceuticals Co. | Delayed released dosage forms |
| WO2006009764A1 (en) * | 2004-06-17 | 2006-01-26 | Amano Enzyme Usa., Ltd. | Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005510542A (ja) * | 2001-11-30 | 2005-04-21 | ファイザー・プロダクツ・インク | 炎症の治療のための、ｉｌ−１／１８阻害剤及びｔｎｆ阻害剤の組み合わせ。 |
| ITMI20012599A1 (it) * | 2001-12-11 | 2003-06-11 | Cosmo Spa | Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int |
| US7879361B2 (en) * | 2005-01-04 | 2011-02-01 | Gp Medical, Inc. | Nanoparticles for drug delivery |
| DE602006020123D1 (de) * | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
-
2007
- 2007-09-07 WO PCT/EP2007/059378 patent/WO2008031770A2/en not_active Ceased
- 2007-09-07 MX MX2009002756A patent/MX2009002756A/es not_active Application Discontinuation
- 2007-09-07 US US12/441,112 patent/US20100004157A1/en not_active Abandoned
- 2007-09-07 EP EP07803323A patent/EP2081555A2/en not_active Withdrawn
- 2007-09-07 RU RU2009113557/15A patent/RU2009113557A/ru not_active Application Discontinuation
- 2007-09-07 KR KR1020097007396A patent/KR20090086060A/ko not_active Withdrawn
- 2007-09-07 JP JP2009527791A patent/JP2010502759A/ja active Pending
- 2007-09-07 CA CA002663548A patent/CA2663548A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07145068A (ja) * | 1991-08-07 | 1995-06-06 | Yeda Res & Dev Co Ltd | 溶解型ｔｎｆ受容体のマルチマー、その製造方法、およびそれを含有する医薬組成物 |
| JPH10503179A (ja) * | 1994-06-24 | 1998-03-24 | イミュネックス・コーポレーション | 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法 |
| JP2003501457A (ja) * | 1999-06-14 | 2003-01-14 | コスモ ソシエタ ペル アチオニ | 制御放出および味感遮蔽経口医薬組成物 |
| WO2005027878A1 (en) * | 2003-09-19 | 2005-03-31 | Penwest Pharmaceuticals Co. | Delayed released dosage forms |
| WO2006009764A1 (en) * | 2004-06-17 | 2006-01-26 | Amano Enzyme Usa., Ltd. | Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11026998B2 (en) | 2014-05-15 | 2021-06-08 | Rani Therapeutics, Llc | Shaped mass composition comprising exenatide |
| JP7565688B2 (ja) | 2014-05-15 | 2024-10-11 | ラニ セラピューティクス， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法 |
| JP2020063301A (ja) * | 2014-05-15 | 2020-04-23 | インキューブ ラブズ， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法 |
| US12018090B2 (en) | 2014-05-15 | 2024-06-25 | Rani Therapeutics, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10953075B2 (en) | 2014-05-15 | 2021-03-23 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies |
| US11718665B2 (en) | 2014-05-15 | 2023-08-08 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| JP2021102660A (ja) * | 2014-05-15 | 2021-07-15 | インキューブ ラブズ， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法 |
| US11291709B2 (en) | 2014-05-15 | 2022-04-05 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising TNF-inhibiting antibodies |
| US11304993B2 (en) | 2014-05-15 | 2022-04-19 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| JP2017521479A (ja) * | 2014-05-15 | 2017-08-03 | ラニ セラピューティクス， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法 |
| JP2018514563A (ja) * | 2015-05-01 | 2018-06-07 | インキューブ ラブズ， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の製作のための薬学的組成物および方法 |
| JP7202070B2 (ja) | 2015-05-01 | 2023-01-11 | ラニ セラピューティクス， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の製作のための薬学的組成物および方法 |
| JP7224917B2 (ja) | 2016-03-31 | 2023-02-20 | ソリッソ ファーマシューティカルズ，インク． | 組成物 |
| JP2023058591A (ja) * | 2016-03-31 | 2023-04-25 | ソリッソ ファーマシューティカルズ，インク． | 組成物 |
| JP7496906B2 (ja) | 2016-03-31 | 2024-06-07 | ソリッソ ファーマシューティカルズ，インク． | 組成物 |
| JP2019514855A (ja) * | 2016-03-31 | 2019-06-06 | ブイエイチスクエアード リミテッド | 組成物 |
| JP2021506894A (ja) * | 2017-12-22 | 2021-02-22 | コスモ・テクノロジーズ・リミテツド | 固体送達組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090086060A (ko) | 2009-08-10 |
| CA2663548A1 (en) | 2008-03-20 |
| EP2081555A2 (en) | 2009-07-29 |
| WO2008031770A3 (en) | 2008-09-12 |
| WO2008031770A2 (en) | 2008-03-20 |
| US20100004157A1 (en) | 2010-01-07 |
| MX2009002756A (es) | 2009-05-25 |
| RU2009113557A (ru) | 2010-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010502759A (ja) | タンパク質物質の経口または直腸投与のための医薬組成物 | |
| KR102376369B1 (ko) | 조성물 | |
| ES2241031T3 (es) | Sistema de suministro de farmacos gastrointestinales. | |
| US6036978A (en) | Controlled release polypeptide compositions and methods of treating inflammatory bowel disease | |
| US9821024B2 (en) | Immunomodulatory compositions | |
| JP2001519379A (ja) | 遅延性総放出胃腸薬物送達システム | |
| JP2001500885A (ja) | 経口遅延型即時放出製剤及びその製造方法 | |
| US20240239856A1 (en) | Compositions, formulations and interleukin production and purification | |
| WO2001078686A1 (en) | Time-release coated solid compositions for oral administration | |
| IE850308L (en) | Multiple dosage formulation | |
| CN102552919A (zh) | 一种给药组合物及其制备和使用方法 | |
| JP2024016193A (ja) | 活性剤の送達のための乾燥剤を含む経口製剤 | |
| JP2023036901A (ja) | 溶液／懸濁液層状化による抗体を含む固形剤形の調製 | |
| AU754996B2 (en) | Long time drug-sustained release preparation | |
| US20200170956A1 (en) | Topical treatment of inflammatory bowel disease using antibodies and fragments thereof | |
| JP5778184B2 (ja) | 上皮増殖因子の経口投与可能薬学的ペレット | |
| CN101534800A (zh) | 用于口服或直肠施用蛋白质物质的药物组合物 | |
| JPWO1994010983A1 (ja) | 下部消化管放出性の経口医薬製剤 | |
| RU2117488C1 (ru) | Твердое инсулинсодержащее лекарственное средство | |
| WO2000016784A1 (en) | Oral drug delivery system for enhancing the bioavailability of activated glycyrrhetin | |
| ITMI20071205A1 (it) | Composizioni farmaceutiche per la somministrazione orale o rettale di sostanze proteiche | |
| Strich | Oral drug delivery systems based on polysaccharides for colon targeting | |
| CA2243863C (en) | Gastrointestinal drug delivery system | |
| Rachmawati et al. | Modification of IL-10 with M6P yields a liver-selective cytokine with antifibrotic activities in rats | |
| CN1187118A (zh) | 经口递送基因构建物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100903 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100903 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120720 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121221 |